STOCK TITAN

Neoleukin Therapeutics, Inc. - NLTX STOCK NEWS

Welcome to our dedicated news page for Neoleukin Therapeutics (Ticker: NLTX), a resource for investors and traders seeking the latest updates and insights on Neoleukin Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Neoleukin Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Neoleukin Therapeutics's position in the market.

Rhea-AI Summary
Neoleukin Therapeutics, Inc. (NASDAQ:NLTX) announced a 1-for-4 reverse stock split to ensure compliance with the minimum bid price requirement of $4.00 per share for initial listing on the Nasdaq Global Market. The reverse stock split will reduce outstanding shares from approximately 9,398,497 to approximately 2,349,624 shares, with an increase in the authorized common stock from 20,000,000 shares to 500,000,000 shares in connection with the anticipated closing of the merger with Neurogene Inc. The reverse stock split will become effective on December 18, 2023, and the common stock is expected to begin trading on a post-reverse stock split basis on the Nasdaq Global Market on December 19, 2023, under the new name Neurogene Inc. and under the new symbol 'NGNE'.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
306.5%
Tags
none
-
Rhea-AI Summary
Neoleukin Therapeutics announces a 1-for-5 reverse stock split to regain compliance with Nasdaq's minimum bid price requirement.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
391.85%
Tags
none
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-20.11%
Tags
acquisition
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
35.85%
Tags
management
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.14%
Tags
clinical trial
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-19.81%
Tags
earnings
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.89%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.72%
Tags
earnings
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.02%
Tags
conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.87%
Tags
conferences earnings
Neoleukin Therapeutics, Inc.

Nasdaq:NLTX

NLTX Rankings

NLTX Stock Data

8.20M
1.36M
0.28%
Biotechnology
Healthcare
Link
United States
Seattle